268600.KQ

Cellivery Therapeutics, Inc. [268600.KQ] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

268600.KQ Stock Summary

In the News

268600.KQ Financial details

Company Rating
-
Market Cap
244.94B
Income
-45.69B
Revenue
25.56B
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
22
Optionable
No
Shortable
Yes
Earnings
13 May 2024
P/E
-4.32
Forward P/E
-
PEG
0.74
P/S
22.03
P/B
-13.28
P/C
-
P/FCF
-5.68
Quick Ratio
0.06
Current Ratio
0.11
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-1.25K
EPS next Y
-
EPS next Q
-
EPS this Y
-70.21%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
7.06%
Revenue last 5Y
55.52%
Revenue Q/Q
33106.68%
EPS Q/Q
271.19%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-126%
ROE
-1155%
ROC
2.71%
Gross Margin
-21%
Oper. Margin
-433%
Profit Margin
-510%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
6680.0-20900.0
52W High
-68.04%
52W Low
0%
RSI
-
Rel Volume
-
Avg Volume
1.15M
Volume
Perf Week
-
Perf Month
-
Perf Quarter
-
Perf Half Y
-29.91%
-
-
-
-
Beta
0.305
-
-
Volatility
0%, 942.55%
Prev Close
0%
Price
6680
Change
0%

Something similar

Top by Market Cap
FB2A.DE
TSLA
CMC.DE
NVDA
TL0.DE
Same Sector
LJPC
3148.T
CHHE
CYAD
GRST
Check Those
KE
STBA
FCOR
8022.HK
FTOCU
Similar Market Cap
200670.KQ
2385.TW
TFAS.JK
BC94.L
CREDITACC.NS

Company Profile

Healthcare Biotechnology
  • Volume Average 1.15M
  • Market Capitalization 244.94B
  • Employee 22
  • CEO Dr. Daewoong Jo Ph.D.
  • Headquarters Seoul,KR
  • IPO Date 2018-11-09
  • Website http://www.cellivery.com

Cellivery Therapeutics, Inc. researches and develops therapeutic drugs for life-threatening lethal diseases, such as cancer, inflammation, metabolic, and neurodegenerative diseases. It develops small molecule, antibody, and vaccine drugs based on its Therapeutic molecule Systemic Delivery Technology. The company was founded in 2014 and is based in Seoul, South Korea.